pegamotecan

camptothecin-di-20-O-ester of PEG(40-kDa)Gly; structure in first source

Also Known As:

PEG-beta-CPT; PEG-beta-camptothecin; PEG-camptothecin; Prothecan; polyethylene glycol-conjugated camptothecin-20-O-glycinate

Networked: 5 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ajani, J A: 1 article (01/2009)
2.	Benson, A B: 1 article (01/2009)
3.	Evans, T R J: 1 article (01/2009)
4.	Falk, S: 1 article (01/2009)
5.	Mena, R R: 1 article (01/2009)
6.	Mulcahy, M F: 1 article (01/2009)
7.	Picus, J: 1 article (01/2009)
8.	Scott, L C: 1 article (01/2009)
9.	Thomas, A L: 1 article (01/2009)
10.	Wright, J: 1 article (01/2009)

Related Diseases

1.	Neoplasms (Cancer) 12/01/1999 - "Secondly, an active member of this series was used to assess the PEG-camptothecin conjugate's efficacy against a battery of solid tumor types. " 01/01/1998 - "In addition, it appeared that more labelled CPT accumulated in solid tumors when delivered in the PEG-beta-CPT form, with greater preference for tumor tissue than normal tissue. " 11/01/2005 - "To determine the maximal tolerated dose and dose-limiting toxicities (DLT) of pegamotecan (polyethylene glycol-camptothecin) in patients with advanced malignancies when administered in cycles of once weekly for 3 of 4 weeks. " 02/10/2003 - "This recent resuscitation of small organic molecule delivery by high molecular weight PEG conjugates was founded on meaningful in vivo testing using established tumor models, and has led to a clinical candidate, PEG-camptothecin (PROTHECAN), an ester based prodrug currently in phase II trials. "
2.	Colorectal Neoplasms (Colorectal Cancer) 01/01/1998 - "Biodistribution studies were performed in nude mice bearing colorectal carcinoma xenografts with tritium-labelled PEG-beta-CPT and CPT injected i.v. PEG-beta-CPT had a blood t1/2alpha of approximately 6 min and a t1/2beta of 10.2 h. "
3.	Adenocarcinoma 01/01/2009 - "A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma." 01/01/2009 - "Eligible patients with locally advanced (inoperable) or metastatic gastric or gastro-oesophageal adenocarcinoma, with measurable disease, ECOG performance status < or =2, with adequate haematological, renal and hepatic function, who had received < or =1 prior chemotherapy regimen for advanced disease, were treated with 7,000 mg/m(2) of pegamotecan as a 1-h infusion every 21 days until disease progression or unacceptable toxicity. "
4.	Disease Progression 01/01/2009 - "Eligible patients with locally advanced (inoperable) or metastatic gastric or gastro-oesophageal adenocarcinoma, with measurable disease, ECOG performance status < or =2, with adequate haematological, renal and hepatic function, who had received < or =1 prior chemotherapy regimen for advanced disease, were treated with 7,000 mg/m(2) of pegamotecan as a 1-h infusion every 21 days until disease progression or unacceptable toxicity. "

Related Drugs and Biologics

1.	pegamotecan
2.	Camptothecin
3.	Tritium
4.	Prodrugs
5.	Esters
6.	2- cyclohexylidenhydrazo- 4- phenyl- thiazole
7.	Polyethylene Glycols (Polyethylene Glycol)

Related Therapies and Procedures

1.	Resuscitation
2.	Drug Therapy (Chemotherapy)